Back to top
more

Syndax Pharmaceuticals (SNDX)

(Real Time Quote from BATS)

$20.72 USD

20.72
320,141

+1.03 (5.23%)

Updated Nov 6, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF

by Zacks Equity Research

The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD

by Zacks Equity Research

The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Syndax Pharmaceuticals Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Plug Power (PLUG) to Report Q4 Earnings: What to Expect?

by Zacks Equity Research

Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.

Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Syndax (SNDX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Syndax (SNDX) delivered earnings and revenue surprises of 10.53% and -0.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Syndax (SNDX) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

    Is the Options Market Predicting a Spike in Syndax (SNDX) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.

      Syndax Pharmaceuticals (SNDX) Reports Q2 Loss

      by Zacks Equity Research

      Syndax (SNDX) delivered earnings and revenue surprises of 18.68% and 0.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares

        by Zacks Equity Research

        Zacks.com highlights: Dollar Tree, Syndax Pharmaceuticals, Financial Partners and Union Bankshares

          Tirthankar Chakraborty headshot

          4 of the Best Stocks to Buy on Earnings Acceleration

          by Tirthankar Chakraborty

          Studies have shown that majority of successful stocks see acceleration in earnings before a positive stock price movement

            Can Syndax (SNDX) Keep the Earnings Streak Alive This Quarter?

            by Zacks Equity Research

            Syndax Pharmaceuticals (SNDX) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.

              Is a Beat in the Cards for Perrigo (PRGO) in Q3 Earnings?

              by Zacks Equity Research

              Perrigo's (PRGO) product acquisitions and new product launches in the Rx segment might boost sales in the coming quarters.

                Celldex (CLDX) to Report Q3 Earnings: What's in the Cards?

                by Zacks Equity Research

                With no approved product in Celldex Therapeutics' (CLDX) portfolio, investor focus will remain on immuno-oncology pipeline, which continues to show impressive results.